Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric MATCH: Ulixertinib in MAPK-Mutated Tumors
NCT03698994Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Nov 2018
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of ulixertinib in solid tumor, non-Hodgkin lymphoma (NHL), histiocytic disorder, sponsored by National Cancer Institute. Started Nov 2018; status: active, not recruiting.
02
Drugs
ulixertinib
03
Conditions
solid tumornon-Hodgkin lymphoma (NHL)histiocytic disorder
Beyond the preview
Go deeper on NCT03698994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03698994.